Answers are grounded in this paper and cite their sources.
Diabetic retinopathy (DR) is a major microvascular complication of diabetes mellitus (DM) and a leading cause of vision loss worldwide. Several risk factors have been implicated in the development and progression of DR, such as longer duration of diabetes, poor glycemic control, hypertension, dyslipidemia, renal impairment, and smoking. Diabetic macular edema is the main cause of visual impairment in patients with diabetic retinopathy. It is defined by retinal thickening from fluid leakage into the retina and can be visualized with optical coherence tomography (OCT). At the molecular level, chronic hyperglycemia triggers several pathogenic mechanisms, including oxidative stress, inflammation, advanced glycation end product formation, protein kinase C activation, and dysregulated vascular endothelial growth factor (VEGF) signaling, leading to blood–retinal barrier breakdown, microvascular dysfunction, and retinal neurodegeneration. Current therapeutic approaches include laser photocoagulation, intravitreal anti-VEGF agents, and corticosteroids, with ongoing research into novel interventions targeting senolytic agents, integrin antagonists, inhibitors of vascular adhesion protein-1, anti-inflammatory therapies targeting interleukin-6 (IL-6) signaling, and plasma kallikrein inhibitors. This review synthesizes the recent evidence on DR epidemiology, risk factors, pathophysiology, and treatment, highlighting the need for comprehensive risk-based screening and multidisciplinary management to mitigate the growing burden of diabetic eye disease.
No takes yet. Share an insight, caveat, or question.
Baiturova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: